Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study
- 393 Downloads
Aromatase inhibitors (AI) have been shown to reduce breast cancer-related mortality in women with estrogen positive (ER+) breast cancer. The use of AIs, however, has been associated with higher rates of hypertension, hyperlipidemia, and cardiovascular (CV) events.
A cross-sectional study of 25 healthy postmenopausal women and 36 women with curative intent breast cancer on an AI was performed to assess endothelial dysfunction, an indicator of risk for CV events. Consented subjects underwent vascular testing using the HDI/Pulse Wave CR-2000 Cardiovascular Profiling System and the EndoPAT2000 system.
Mean age was 61.7 and 59.6 years (cases, controls). Most subjects were Caucasian and overweight. Controls had a lower mean systolic blood pressure (128.6 mmHg vs. 116.2 mmHg, p = 0.004). Median estradiol levels were reduced in cases (2 vs. 15 pg/ml, p < 0.0001). EndoPAT ratio (0.8 vs. 2.7, p < 0.0001) was significantly reduced in cases as compared to controls. Median large artery elasticity (12.9 vs. 14.6 ml/mmHg × 10, p = 0.12) and small artery elasticity (5.2 vs. 7.0 ml/mmHg × 100, p = 0.07) were also reduced though not statistically significant. There was no correlation between use of chemotherapy, radiation therapy, type of AI, or duration of AI use and endothelial function. When adjusting for differences in blood pressure, results remained significant.
Breast cancer cases on AIs have reductions in endothelial function, a predictor of adverse CV disease. Impact: Vascular function changes in breast cancer cases on AIs compared to postmenopausal women. Further work is needed to evaluate vascular changes over time.
KeywordsCardiotoxicity Breast cancer Aromatase inhibitors Endothelial function Vascular function
The work in this paper was supposed by the Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) NIH# K12-HD055887 Grant.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. doi: 10.1016/S0140-6736(11)61625-5 CrossRefGoogle Scholar
- 6.Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 12(12):1101–1108. doi: 10.1016/S1470-2045(11)70270-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE et al (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570. doi: 10.1016/S0140-6736(07)60200-1 CrossRefPubMedGoogle Scholar
- 8.Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S et al (2017) Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 28(3):487–496. doi: 10.1093/annonc/mdw673 PubMedGoogle Scholar
- 12.Blaes AH, Mulrooney DA, Vogel RI, Peterson BA, Yee D, Neglia JP et al (2014) Arterial elasticity in testicular cancer survivors. J Clin Oncol 32:5Google Scholar
- 13.Duprez DA, Jacobs DR Jr, Lutsey PL, Bluemke DA, Brumback LC, Polak JF et al (2011) Association of small artery elasticity with incident cardiovascular disease in older adults: the multi-ethnic study of atherosclerosis. Am J Epidemiol 174(5):528–536. doi: 10.1093/aje/kwr120 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Shechter M, Issachar A, Marai I, Koren-Morag N, Freinark D, Shahar Y et al (2009) Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int J Cardiol 134(1):52–58. doi: 10.1016/j.ijcard.2008.01.021 CrossRefPubMedGoogle Scholar